On October 09, 2017 Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, reported data presentations relating to its technology platforms to be given at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 32ND Annual Meeting taking place in National Harbor, Maryland, November 8-12, 2017 (Press release, Aduro Biotech, OCT 9, 2017, View Source [SID1234520811]).

Poster 335: Characterization of a novel differentiated anti-CTLA-4 antibody (ADU-1604) in vitro and in vivo
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m. EST
Poster Hall Location: Prince George’s Exhibition Hall DE

Poster 61: Cellular and genomic disease signature of peripheral blood mononuclear cells in patients with malignant pleural mesothelioma
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m. EST
Poster Hall Location: Prince George’s Exhibition Hall DE

Poster 133: A heterologous prime-boost vaccination strategy combining a Listeria and DNA-based vaccine encoding prostatic acid phosphatase (PAP) elicits a strong antigen-specific, anti-tumor response
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m. EST
Poster Hall Location: Prince George’s Exhibition Hall DE
Per SITC (Free SITC Whitepaper) guidelines, abstracts are embargoed until 8:00 a.m. EST on November 7, 2017. To view abstracts, please visit the SITC (Free SITC Whitepaper) website at View Source